New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
13:07 EDTSGENSeattle Genetics weakness a buying opportunity, says Credit Suisse
Credit Suisse said Seattle Genetics top-line AETHERA data was significantly positive for the primary endpoint and expects full results in December at ASH to provide a meaningful update. The firm would use weakness as a buying opportunity and reiterates its Outperform rating and $51 price target.
12:59 EDTSGENSeattle Genetics positive data largely as expected, says Piper Jaffray
Piper Jaffray says the Seattle Genetics' positive top-line data from the Phase III ATHERA trial of ADCETRIS for consolidation therapy in high risk Hodgkin's lymphoma patients following stem cell transplant was largely as expected. Piper sees the potential for label expansion, but keeps an Underweight rating on the stock with a $26 price target.
08:25 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Meetings to be held in Baltimore/Philadelphia on September 29 hosted by Deutsche Bank.
06:49 EDTSGENSeattle Genetics, Takeda announce positive data from Phase 3 trial of Adcetris
Seattle Genetics and Takeda Pharmaceutical announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo. The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL. The AETHERA trial met its primary endpoint with ADCETRIS treatment resulting in a statistically significant improvement in progression-free survival versus placebo as assessed by an independent central review committee, which equates to a 75% improvement in PFS. PFS was assessed after a minimum of two years post initiation of treatment for all study patients. A pre-specified interim analysis of overall survival showed no statistically significant difference between the treatment arms. Patients on both study arms with progression of HL received a variety of subsequent therapies. Notably, most patients on the placebo arm received ADCETRIS after progression. A further analysis of overall survival is planned in 2016.
06:35 EDTEXAMExamWorks pullback a buying opportunity, says Deutsche Bank
Subscribe for More Information
05:47 EDTSGENSeattle Genetics to host conference call
Subscribe for More Information
September 26, 2014
17:59 EDTSGENSeattle Genetics up nearly 4% after hours after setting date for ADCETRIS data
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:56 EDTTRVNTrevena management to meet with JMP Securities
Subscribe for More Information
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
September 25, 2014
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:47 EDTEXAMExamWorks management to meet with Deutsche Bank
Subscribe for More Information
September 24, 2014
09:07 EDTSGENSeattle Genetics reports additional data from Phase 1 trial of ADCETRIS
Subscribe for More Information
08:23 EDTEXAMExamWorks management to meet with Deutsche Bank
Meetings to be held in Frankfurt/Milan on September 24 hosted by Deutsche Bank.
September 23, 2014
08:52 EDTEXAMExamWorks management to meet with Deutsche Bank
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.
09:50 EDTEXAMExamWorks management to meet with Deutsche Bank
Subscribe for More Information
07:01 EDTTRVNTrevena enters into $35M tranched term loan credit facility
Subscribe for More Information
September 19, 2014
06:19 EDTBCRC.R. Bard management to meet with JMP Securities
Meeting to be held in Boston on September 23 hosted by JMP Securities.
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use